# Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

> **NCT03346135** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 31 (actual)

## Conditions studied

- Plasma Cell Myeloma
- Secondary Amyloidosis

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Daratumumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT03346135
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-17
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346135, "Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03346135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*